In a report issued on June 17, Jason Kolbert from Dawson James maintained a Hold rating on Soligenix (SNGX – Research Report). The company’s shares closed last Friday at $0.57.
According to TipRanks.com, Kolbert has 0 stars on 0-5 stars ranking scale with an average return of -3.6% and a 34.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Lineage Cell Therapeutics, and Citius Pharmaceuticals.
The word on The Street in general, suggests a Hold analyst consensus rating for Soligenix.
See Insiders’ Hot Stocks on TipRanks >>
Soligenix’s market cap is currently $24.44M and has a P/E ratio of -1.65.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SNGX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Soligenix, Inc. engages in the development and commercialization of products to treat rare disease. It operates through the following segments: BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment offers photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Vaccines/BioDefense segment includes active development programs for RiVax, ricin toxin vaccine candidate, OrbeShield, GI acute radiation syndrome therapeutic candidate, and SGX943, melioidosis therapeutic candidate. The company was founded in 1987 and is headquartered Princeton, NJ.
Read More on SNGX:
- Dawson James Sticks to Its Buy Rating for Genius Brands International (GNUS)
- DraftKings Stock: A Wager for the Long-Haul
- Dawson James Thinks Anavex Life Sciences’ Stock is Going to Recover
- Dawson James Thinks Athersys’ Stock is Going to Recover
- Maxim Group Thinks Medivir AB’s Stock is Going to Recover